Nuvectis Pharma initiates NXP900 Phase 1b program, reports successful Phase 1a results.
ByAinvest
Tuesday, Nov 4, 2025 8:20 am ET1min read
NVCT--
• Nuvectis Pharma initiates NXP900 Phase 1b program in advanced cancers • Single-agent study underway for preliminary clinical efficacy evidence • Combination portion of the program expected by year-end • NXP900 Phase 1a dose escalation study completed with robust pharmacodynamic responses • NXP900 clinical drug-drug interaction study in healthy volunteers completed • Poster presentations at AACR-NCI-EORTC International Conference highlight NXP900's clinical profile
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet